Command Palette

Search for a command to run...

SYNGENE
633.9(-2.67%)
1W: +4.57%

Syngene International Quarterly Results

Charts

YoY Net Sales (Quarterly)
Operating Margin
EPS Growth

Pros & Cons

POSITIVES
  • Revenue for the latest quarter shows a year-on-year increase, reflecting strong demand in biopharmaceuticals.
  • Improved operational efficiency has led to a reduction in cost of goods sold, enhancing gross margins.
  • Strong cash flow generation supports ongoing investments and potential dividend payments, enhancing shareholder value.
NEGATIVES
  • Revenue growth has slowed down compared to previous quarters, indicating potential market saturation.
  • Operating margins have contracted, raising concerns about cost management and profitability.
  • R&D expenditure remains high, which, while necessary, could strain short-term financials if not managed effectively.

Quarterly Results Data (Numbers are in Crore)

FieldTrendSep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25
Revenue
910.10853.50916.90789.70891943.701,018874.50
Expenses
773.60740.90724738.50774.50782.90796.40790.90
Operating Profit
136.50112.60192.9051.20116.50160.80221.6083.60
Other Income
21.6029.3016.1018.1020.802018.9017.70
Interest
1310.8012.9011.7013.1012.4015.9011.60
Depreciation
104.60108.10111.10106.90110.90108.70106.10111.20
Profit Before Tax
150.70138.20209101.30137.30180.80240.50101.30
Tax
34.2026.7020.4025.6031.2049.7057.2014.60
Net Profit
116.50111.50188.6075.70106.10131.10183.3086.70
Eps in Rs
2.902.784.701.892.643.274.562.16

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.